Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Marconi who wrote (11583)	7/16/1998 8:43:00 AM
From: Franco Battista	Read Replies (1) \| Respond to of 18691

Hello Marconi. IMO Zonagen filing for FDA approval is a lose-lose situation for the company. If Vasomax is rejected, the stock tanks. If it is approved, it faces the competition of Viagra- an oral drug that has been on the market for almost six months and has the lion's share. Vasomax was approved in Mexico a few months back, and even though it sells much cheaper than Viagra, has been totally ignored. The FDA filing removes the speculation on the stock and forces Zonagen to face the realities of the market. Only problem IMO is the small float and manipulation on the stock making timing very difficult on this dog.

To: Marconi who wrote (11583)	7/16/1998 12:33:00 PM
From: Hank	Read Replies (2) \| Respond to of 18691

Marconi, ZONA is a manipulated stock. There fore, if you short it, you should prepared to either trade it aggressively or stay short for the long haul. I don't think it will tank totally until a rejection for Vasoscam is handed down. I think the chances of Vasoscam getting FDA approval are slim to none. The efficacy of a drug in practice is often lower than what is initially seen in clinical trials and the FDA is aware of this. Vasoscam only shows a 12% efficacy above and beyond placebo and the validity of those numbers are very questionable. This is a very line upon which to base an FDA approval. In the long rung, being short is the way to go with this one. Hank